<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522651</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-291-0102</org_study_id>
    <secondary_id>2011-001134-42</secondary_id>
    <nct_id>NCT01522651</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)</brief_title>
  <official_title>A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether treatment with ranolazine or low dose
      dronedarone reduces atrial fibrillation burden (AFB) in subjects with paroxysmal atrial
      fibrillation (PAF), and whether combination therapy (ranolazine and low dose dronedarone) is
      superior to individual drug therapy in reducing AFB.

      This phase 2 clinical trial will be conducted over 16 weeks and involves a Screening period
      (4 weeks) and a Treatment period (12 weeks). The final follow up visit will occur 2 weeks
      after the end of the Treatment period. Primary and Secondary endpoints will be evaluated
      according to treatment group, clinic visit period, and the overall Treatment period. Safety
      analyses will be conducted at each clinic visit, and include: cardiac rhythm monitoring, ECG
      testing, laboratory evaluation, and symptom and adverse event assessment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of ranolazine and of low dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Atrial Fibrillation Burden (AFB) is defined as the total time a subject is in atrial tachycardia/atrial fibrillation (AT/AF) expressed as a percentage of total recording time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AFB for each visit period (Weeks 4, 8 and 12)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of atrial fibrillation (AF) episodes, duration of AF episodes, and ventricular rate during AF episodes</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular rate over 12 weeks of treatment and for each visit period (Weeks 4, 8, and 12)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of ventricular pacing</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of atrial pacing</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of persistent AF</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of electrical cardioversion</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic episodes</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects who have ≥ 30% (≥ 50%) reduction from baseline in AFB</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects who have total duration of AF episodes ≥ 5.5 hours per day at any point during the Treatment period</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ranolazine placebo plus dronedarone placebo for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine plus dronedarone placebo for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dronedarone low dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine placebo plus dronedarone low dose 1 for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranolazine + dronedarone low dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine plus dronedarone low dose 1 for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranolazine + dronedarone low dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine plus dronedarone low dose 2 for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Ranolazine 750 mg tablet administered orally twice daily</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_label>Ranolazine + dronedarone low dose 1</arm_group_label>
    <arm_group_label>Ranolazine + dronedarone low dose 2</arm_group_label>
    <other_name>Ranexa®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronedarone low dose 1</intervention_name>
    <description>Dronedarone 225 mg capsule administered orally twice daily</description>
    <arm_group_label>Dronedarone low dose 1</arm_group_label>
    <arm_group_label>Ranolazine + dronedarone low dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronedarone low dose 2</intervention_name>
    <description>Dronedarone 150 mg capsule administered orally twice daily</description>
    <arm_group_label>Ranolazine + dronedarone low dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine placebo</intervention_name>
    <description>Placebo to match ranolazine administered orally twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Dronedarone low dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronedarone placebo</intervention_name>
    <description>Placebo to match dronedarone administered orally twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ranolazine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18 years and older

          -  Have the ability to understand and sign a written informed consent form, which must be
             obtained prior to initiation of study procedures

          -  History of PAF documented within the prior 12 months

             — Patients with PAF undergoing cardioversion greater than 4 weeks prior to Screening
             are eligible

          -  Implanted (at least 3 months prior to Screening) dual chamber programmable pacemakers
             with AF detection capabilities

          -  AFB ≥ 1% and ≤ 70% between the last clinic evaluation and Screening (minimum of 1
             month observation period) and AFB ≥ 2% and ≤ 70% during the Run in period

          -  Sexually active females of childbearing potential must agree to utilize effective
             methods of contraception during heterosexual intercourse throughout the treatment
             period and for 14 days following discontinuation of the study medication

        Exclusion Criteria:

        Disease - specific:

          -  Persistent AF or Permanent AF

          -  History of atrial flutter or atrial tachycardia without successful ablation

          -  Other acutely reversible causes of AF, including but not limited to: hyperthyroidism,
             pericarditis, myocarditis, or pulmonary embolism

          -  New York Heart Association (NYHA) Class III and IV heart failure or NYHA Class II
             heart failure with a recent decompensation requiring hospitalization or referral to a
             specialized heart failure clinic within 4 weeks prior to Screening.

          -  Recent history of left ventricular ejection fraction (LVEF) &lt; 40%

          -  Myocardial infarction, unstable angina, or coronary artery bypass graft (CABG) surgery
             within three months prior to Screening or percutaneous coronary intervention (PCI)
             within 4 weeks prior to Screening

          -  Clinically significant valvular disease in the opinion of the Investigator

          -  Stroke within 3 months prior to Screening

          -  History of serious ventricular arrhythmias (eg, sustained ventricular tachycardia,
             ventricular fibrillation) within 4 weeks prior to Screening

          -  Family history of long QT syndrome

          -  QTc ≥ 500 msec (Bazett) at Screening ECG if in sinus rhythm (SR). If in AF, evidence
             of QTc ≥ 500 msec (Bazett) within 4 weeks prior to Screening

          -  Prior heart transplant

          -  Cardiac ablation within 4 months prior to Screening, or planned ablation during the
             course of the study

        Concomitant medications/food

          -  Need for concomitant treatment during the trial, with drugs or products that are
             strong inhibitors of CYP3A, or inducers of CYP3A

             — Such medications should be discontinued 5-half lives prior to the Run-in period

          -  Use of grapefruit juice or Seville orange juice during the study

          -  Use of Class I and Class III antiarrhythmic drugs other than amiodarone within 5-half
             lives prior to the Run-in period

          -  Use of amiodarone within 3 months prior to Screening

          -  Use of drugs that prolong the QT interval

          -  Previous use of ranolazine or dronedarone within 2 months prior to screening

          -  Prior use of ranolazine or dronedarone which was discontinued for safety or
             tolerability

          -  Use of dabigatran during the study

          -  Use of digitalis preparations (eg, digoxin) during the study

          -  Use of a greater than 1000 mg total daily dose of metformin during the study

        Laboratory tests:

          -  Hypokalemia (serum potassium &lt; 3.5 mEq/L) at Screening that cannot be corrected to a
             level of potassium ≥ 3.5 mEq/L prior to randomization

          -  Moderate and severe hepatic impairment (ie, Child-Pugh Class B and C), abnormal liver
             function test defined as ALT, AST, or bilirubin &gt; 2 x ULN at Screening

          -  Severe renal impairment defined as creatinine clearance ≤ 30 mL/min at Screening

        Others:

          -  Females who are pregnant or are breastfeeding

          -  In the judgment of the Investigator, any clinically-significant ongoing medical
             condition that might jeopardize the subject's safety or interfere with the study,
             including participation in another clinical trial within the previous 30 days using a
             therapeutic modality which could have potential residual effects that might confound
             the results of this study

          -  Any device-related technical issue which in the judgment of the investigator would
             disrupt adequate data collection or interpretation (eg, anticipated pulse generator
             change or lead revision)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cardiovascular Clinical Research, Gilead Sciences</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Utica</city>
        <state>New York</state>
        <zip>13501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60594</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ingolstadt</city>
        <zip>85049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lubeck</city>
        <zip>D23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ashkelon</city>
        <state>Ashqelon</state>
        <zip>78287</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Afula</city>
        <state>Zefat</state>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Como</city>
        <zip>22020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>90-553</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lódz</city>
        <state>Lodzkie</state>
        <zip>90-553</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kraków</city>
        <state>Malopolskie</state>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>01-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Sopot</city>
        <state>Pomorskie</state>
        <zip>81-717</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Zabrze</city>
        <state>Slaskie</state>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Posnan</city>
        <state>Wielkopolskie</state>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <state>Zachodniop</state>
        <zip>70-203</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>91-425</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2012</study_first_posted>
  <disposition_first_submitted>August 7, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 7, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 11, 2014</disposition_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Ranolazine</keyword>
  <keyword>Dronedarone</keyword>
  <keyword>Dual Chamber Pacemakers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

